$19.5 M

AGRX Mkt cap, 22-Jun-2018
Agile Therapeutics Net income (Q1, 2018)-6.8 M
Agile Therapeutics EBIT (Q1, 2018)-7 M
Agile Therapeutics Cash, 31-Mar-201828.3 M

Agile Therapeutics Financials

Agile Therapeutics Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

R&D expense

13.4 m25.6 m20.9 m14.4 m

General and administrative expense

5.2 m7.5 m8.8 m12.4 m

Operating expense total

18.5 m33.1 m29.7 m26.8 m

EBIT

(18.5 m)(33.1 m)(29.7 m)(26.8 m)

Interest expense

1.6 m2.1 m2.4 m1.9 m

Interest income

2.6 k5 k117 k282 k

Net Income

(16.1 m)(30.3 m)(28.7 m)(28.3 m)

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

R&D expense

2.4 m4.6 m5.4 m6.2 m7.2 m4.9 m5.6 m4.9 m4.7 m3.8 m4 m

General and administrative expense

1.1 m1.4 m1.6 m1.8 m1.8 m2.1 m2.3 m2.2 m2.4 m3.2 m3.1 m

Operating expense total

3.5 m6 m7 m8 m9 m7 m7.8 m7.1 m7.1 m7 m6.7 m7 m

EBIT

(3.5 m)(6 m)(7 m)(8 m)(9 m)(7 m)(7.8 m)(7.1 m)(7.1 m)(7 m)(6.7 m)(7 m)

Interest expense

403.5 k392 k425.8 k547.6 k551.7 k548 k548 k784 k546 k504 k459 k368 k

Interest income

82 1.3 k1.2 k1.3 k1.2 k17 k33 k33 k47 k61 k78 k97 k

Income tax expense

477 k

Net Income

(3.7 m)(6.4 m)(8.5 m)(8.5 m)(9.4 m)(7.3 m)(8.4 m)(7.8 m)(7.5 m)(7.4 m)(7.1 m)(6.8 m)

Agile Therapeutics Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

40.2 m34.4 m48.8 m36 m

Accounts Receivable

539 m

Current Assets

41 m38.1 m51.5 m36.7 m

PP&E

12 m12.3 m12.3 m13.9 m

Total Assets

54.8 m50.7 m63.9 m50.6 m

Accounts Payable

2.6 m2.4 m2.1 m2.8 m

Current Liabilities

9 m7.9 m10.7 m14.3 m

Total Liabilities

14.3 m

Additional Paid-in Capital

170.4 m194.5 m235.8 m258.1 m

Retained Earnings

(134.4 m)(164.7 m)(193.5 m)(221.8 m)

Total Equity

36 m29.7 m42.3 m36.3 m

Financial Leverage

1.5 x1.7 x1.5 x1.4 x

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

53.5 m45.7 m53.9 m46.4 m39.4 m65.5 m59.2 m51.7 m41.7 m33.9 m43.8 m28.3 m

Inventories

1.6 m

Current Assets

54.2 m47 m54.4 m47.2 m40.7 m68.5 m61.3 m54.8 m44.3 m34.5 m45 m29 m

PP&E

12.3 m12.3 m12.3 m12.3 m12.8 m13.9 m

Total Assets

66.3 m60.9 m68.7 m61.7 m55.1 m80.9 m73.6 m67.1 m56.6 m47.3 m58.4 m42.9 m

Accounts Payable

2.3 m2.7 m3.3 m2.7 m4.3 m2.9 m3 m2.9 m3.2 m3 m2.8 m2.1 m

Current Liabilities

5.3 m7.2 m4.8 m5.2 m6.9 m8.4 m10.1 m8.4 m11.6 m10.2 m11 m12.3 m

Additional Paid-in Capital

169.5 m169.9 m191.7 m192.6 m193.6 m233 m234 m234.9 m236.6 m237.6 m257.1 m259.2 m

Retained Earnings

(121.2 m)(127.5 m)(142.9 m)(151.4 m)(160.8 m)(172 m)(180.5 m)(188.3 m)(201 m)(208.4 m)(215.5 m)(228.6 m)

Total Equity

48.8 m41.2 m32.7 m61 m53.5 m46.7 m35.6 m29.1 m41.6 m30.6 m

Financial Leverage

1.4 x1.5 x1.7 x1.3 x1.4 x1.4 x1.6 x1.6 x1.4 x1.4 x

Agile Therapeutics Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(16.1 m)(30.3 m)(28.7 m)(28.3 m)

Depreciation and Amortization

12.6 k18 k19 k23 k

Inventories

(2.3 m)(1.2 m)922 k

Accounts Payable

2.6 m1.3 m362 k(2.5 m)

Cash From Operating Activities

(14.5 m)(25.5 m)(23.3 m)(24.6 m)

Purchases of PP&E

(95.7 k)(290 k)(31 k)(1.3 m)

Cash From Investing Activities

(95.7 k)(290 k)(31 k)(1.3 m)

Cash From Financing Activities

52.7 m20 m37.7 m13.1 m

Interest Paid

1.4 m1.5 m1.5 m

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Net Income

(2.9 m)(9.2 m)(8.5 m)(17 m)(26.4 m)(7.3 m)(15.7 m)(23.5 m)(7.5 m)(15 m)(7.1 m)(6.8 m)

Depreciation and Amortization

5 k7.7 k5 k10.1 k14.3 k4 k9 k14 k5 k11 k6 k

Inventories

1.6 m

Accounts Payable

1.6 m2.2 m724.3 k1.2 m3 m(771 k)(768 k)(648 k)348 k(1.2 m)2.8 m(269 k)

Cash From Operating Activities

(5.6 m)(13.2 m)(20.4 m)(6.7 m)(13 m)(20.4 m)(6 m)(11.9 m)(18.8 m)(5.7 m)

Purchases of PP&E

(6.7 k)(42.3 k)(188.6 k)(274.1 k)(288.4 k)(2 k)(20 k)(25 k)(5 k)(450 k)(276 k)

Cash From Investing Activities

(6.7 k)(42.3 k)(188.6 k)(274.1 k)(288.4 k)(2 k)(20 k)(25 k)(5 k)(450 k)(771 k)(276 k)

Long-term Borrowings

(15.8 m)(15.8 m)(15.8 m)(993 k)(2.5 m)(4 m)

Cash From Financing Activities

52.6 m52.6 m19.5 m19.7 m19.9 m37.8 m37.8 m37.7 m(993 k)(2.4 m)14.6 m(1.6 m)

Interest Paid

690 k1 m339.3 k718.8 k1.1 m375 k755 k1.1 m368 k713 k1 m239 k

Agile Therapeutics Ratios

USDY, 2018

Financial Leverage

1.4 x
Report incorrect company information

Agile Therapeutics Operating Metrics

FY, 2016

Patents (US)

13

Patents (foreign)

45

Phase I Trials Products

3

Phase II Trials Products

1

Phase III Trials Products

1
Report incorrect company information